Mustafa Dinckal

Urologist | Medical Doctor M.D. | Fellow of @EBU_urology FEBU | PhD student @UniversiteEge | Fisherman |Photographer | Former Visiting scholar @MoffittNews

[Mustafa Dinckal @DinckalMD]

@MDPIOpenAccess

[Mustafa Dinckal @DinckalMD]

📢 Our review is now published!

Patient and Technology Selection for Focal Therapy in Prostate Cancer

🔗 https://t.co/OW04ffjyoR

@Alice_YuMD @UroR_Pessoa @JulioPowSangMD @Cancers_MDPI #prostatecancer #focaltherapy

[Mustafa Dinckal @DinckalMD]

This review summarizes current evidence on:
✅ Patient selection
✅ mpMRI, PSMA PET & micro-ultrasound
✅ Ablation technologies
✅ Future directions including AI-assisted treatment planning

We hope it will serve as a practical resource for clinicians working in prostate cancer.

[Mustafa Dinckal @DinckalMD]

@KidneyCancer @SpiessPhilippe @MoffittNews Congratulations Dr. Spiess! Very well deserved!

[Mustafa Dinckal @DinckalMD]

Plasma urotensin-2 levels as a potential biomarker in... : Medicine https://t.co/7Ckfpxwv0b

[Mustafa Dinckal @DinckalMD]

🧬 Thrilled to share our new study published in Medicine!

🎯 Our study reveals that plasma UT-2 levels are significantly elevated in metastatic prostate cancer patients - a potential new biomarker for identifying cancer spread.

[Mustafa Dinckal @DinckalMD]

@UrogerliMD @UroOnc @AmerUrological @BladderCancerUS @IBCG_BladderCA @MoffittGUOnc @MoffittNews Congratulations! @UrogerliMD Very well deserved.

[Mustafa Dinckal @DinckalMD]

@MoffittNews @SpiessPhilippe Congratulations! Well deserved @SpiessPhilippe

[Mustafa Dinckal @DinckalMD]

@DrCigdemDinckal @semihaxozgul

[Mustafa Dinckal @DinckalMD]

Clinical significance of urotensin 2 plasma level in patients diagnosed with prostate cancer. | Journal of Clinical Oncology https://t.co/Uo8KaX2hoe

[Yüksel Ürün @DrYukselUrun]

Congrats to @DrCigdemDinckal and colleagues! 👏
The clinical significance of urotensin 2 plasma levels in prostate cancer, highlighting its potential as a prognostic biomarker! #GU25 #cancer #oncology
@asco @OncoAlert

[Fuat Bicer MD, PhD @fuatbcr]

Congratulations Dr. @DrCigdemDinckal for the great poster. @ASCO @ConquerCancerFd #GU25

[Mustafa Dinckal @DinckalMD]

⭐️ Honored to be part of this groundbreaking research! @ASCO #GU25

📌This is the first case-control study by @DrCigdemDinckal investigating the clinical significance of plasma Urotensin-2 in prostate cancer

📌Findings suggest its potential as a biomarker for metastatic disease

[Cigdem Dinckal @DrCigdemDinckal]

@ASCO #GU25 “Urotensin 2 is a new biomarker for prostate cancer?”
Great Poster Session with @AkashPatnaik7 @UChicagoHemOnc

[Cigdem Dinckal @DrCigdemDinckal]

#GU25 “Is UT2 a new biomarker for prostate cancer?” Great poster session with @yekeduz_emre @nataliagandur

[Emre Yekedüz @yekeduz_emre]

If you nearby please come on down to check this poster by @DrCigdemDinckal @ASCO #GU25

🌟Urotension-2 is a promising biomarker in patients with #ProstateCancer

@DrYukselUrun @neerajaiims @nataliagandur

[Philippe spiess @SpiessPhilippe]

The role of neoadjuvant systemic therapy for high grade upper tract urothelial carcinoma: Results from the upper tract collaborative network (UCAN) - ScienceDirect https://t.co/kWVIAerOuf

[Mustafa Dinckal @DinckalMD]

@ScholarshipfPhd English

[Roger Li @UrogerliMD]

Oncolytic Virotherapy Plus Nivolumab Is Safe in Muscle-Invasive Bladder Cancer | Cancer Discovery News | American Association for Cancer Research https://t.co/BMcEE1564h

[Scholarship for PhD @ScholarshipfPhd]

Fundamentals of Good Writing: A Handbook of Modern Rhetoric

Drop a "BOOK" in the comments, and I'll send the link to you via DM! 💬